Structure Therapeutics Inc. (GPCR)

48.01 -0.16 (-0.33%) As of 10:15AM EDT. Market open.

Structure Therapeutics Inc.

601 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
United States
(650) 457-1978
https://structuretx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 111

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Raymond C. Stevens Ph.D.	CEO & Director	890.38k	N/A	1964
Mr. Jun S. Yoon	Co- Founder, CFO & Secretary	627.64k	N/A	1978
Dr. Mark A. Bach M.D., Ph.D.	Chief Medical Officer	672.06k	N/A	1957
Dr. Yingli Ma Ph.D.	Chief Technology Officer	497.58k	N/A	1974
Dr. Xichen Lin Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Mr. Tony Peng	Senior Vice President of Legal	N/A	N/A	N/A
Mr. Bob Gatmaitan	Senior Vice President of People	N/A	N/A	N/A
Dr. Hui Lei Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Dr. Fang Zhang Ph.D.	Executive VP & Head of Biology	N/A	N/A	N/A
Ms. Lani Ibarra	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Corporate governance

Structure Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.